Low dose IL-2 for treating autoimmune-related or inflammatory disorders
David Klatzmann, Paris (FR); David Saadoun, Neuilly sur Seine (FR); Patrice Cacoub, Le Perreux (FR); Michèle Rosenzwajg, Paris (FR); Eliane Piaggio, Paris (FR); Gilbert Bensimon, Villejuif (FR); and Claude Bernard, Malakoff (FR)
Assigned to INSERM (Institut National de la Sante et de la Recherche Medicale), Paris (FR); Assistance Publique-Hopitaux De Paris, Paris (FR); and Sorbonne Universite, Paris (FR)
Filed by INSERM (Institut National de la Sante et de la Recherche Medicale), Paris (FR); Assistance Publique—Hopitaux De Paris, Paris (FR); and SORBONNE UNIVERSITE, Paris (FR)
Filed on Jan. 6, 2023, as Appl. No. 18/151,383.
Application 18/151,383 is a continuation of application No. 16/925,983, filed on Jul. 10, 2020, granted, now 11,559,566.
Application 16/925,983 is a continuation of application No. 16/361,902, filed on Mar. 22, 2019, granted, now 10,765,723, issued on Sep. 8, 2020.
Application 16/361,902 is a continuation of application No. 15/588,226, filed on May 5, 2017, granted, now 10,293,028, issued on May 21, 2019.
Application 15/588,226 is a continuation of application No. 14/004,211, granted, now 9,669,071, issued on Jun. 6, 2017, previously published as PCT/EP2012/054174, filed on Mar. 9, 2012.
Claims priority of provisional application 61/451,663, filed on Mar. 11, 2011.
Claims priority of application No. 11305269 (EP), filed on Mar. 11, 2011.
Prior Publication US 2023/0149512 A1, May 18, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/20 (2006.01)
CPC A61K 38/2013 (2013.01)
18 Claims
1. A method for stimulating regulatory T lymphocytes (Treg) in a human patient, the method comprising administering an interleukin-2 (IL-2) to a human patient in need thereof at a dose of between 0.1 and 3.5 MIU/day in a first course of treatment, wherein the first course of treatment increases Treg cells in the subject; and wherein the first course of treatment is followed by a maintenance dose of the IL-2.